XML 48 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Segments of Business (Tables)
 3 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Information
Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals was as follows:
 Three Months Ended June 30,
(In millions)20252024
Segment revenues (1)
U.S. Pharmaceutical$89,954 $71,715 
Prescription Technology Solutions1,434 1,241 
Medical-Surgical Solutions2,701 2,636 
International3,738 3,691 
Total revenues$97,827 $79,283 
Other segment expense, net (2)
U.S. Pharmaceutical (3)
$89,227 $70,934 
Prescription Technology Solutions
1,181 1,038 
Medical-Surgical Solutions
2,480 2,448 
International
3,646 3,601 
Total other segment expense, net$96,534 $78,021 
Segment operating profit
U.S. Pharmaceutical$727 $781 
Prescription Technology Solutions253 203 
Medical-Surgical Solutions221 188 
International92 90 
Subtotal1,293 1,262 
Corporate expenses, net (4)
(193)(103)
Interest expense(49)(75)
Income before income taxes$1,051 $1,084 
Segment depreciation and amortization (5)
U.S. Pharmaceutical$63 $60 
Prescription Technology Solutions21 21 
Medical-Surgical Solutions22 23 
International14 30 
Corporate37 35 
Total segment depreciation and amortization$157 $169 
Segment expenditures for long-lived assets (6)
U.S. Pharmaceutical$73 $28 
Prescription Technology Solutions1 4 
Medical-Surgical Solutions25 51 
International13 25 
Corporate77 59 
Total segment expenditures for long-lived assets$189 $167 
(1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment’s total revenues, approximately 38% of the RxTS segment’s total revenues, less than 1% of the Medical-Surgical Solutions segment’s total revenues, and less than 1% of the International segment’s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.
(2)Other segment expense, net includes cost of sales, total operating expenses, as well as other income, net, for the Company’s reportable segments.
(3)The Company’s U.S. Pharmaceutical other segment expense, net includes the following:
•a provision for bad debts of $189 million for the three months ended June 30, 2025 related to the bankruptcy of the Company’s customer Rite Aid Corporation (including certain of its subsidiaries, “Rite Aid”). This charge was recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Condensed Consolidated Statements of Operations;
•cash receipts for the Company’s share of antitrust legal settlements of $8 million and $90 million for the three months ended June 30, 2025 and 2024, respectively. These gains were recorded within “Cost of sales” in the Company’s Condensed Consolidated Statements of Operations;
•a credit of $7 million and $2 million related to the last-in, first-out method of accounting for inventories for the three months ended June 30, 2025 and 2024, respectively. These amounts were recorded within “Cost of sales” in the Company’s Condensed Consolidated Statements of Operations;
•a charge of $57 million for the three months ended June 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 11, “Commitments and Contingent Liabilities,” and
•a loss of $43 million for the three months ended June 30, 2024 related to one of the Company’s equity method investments, which was recorded within “Other income, net” in the Company’s Condensed Consolidated Statement of Operations.
(4)Corporate expenses, net includes the following:
•a net gain of $110 million for the three months ended June 30, 2024 related to the Company’s investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in Financial Note 10, “Fair Value Measurements;”
•a net charge of $55 million for the three months ended June 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 11, “Commitments and Contingent Liabilities;” and
•restructuring charges of $29 million and $1 million for the three months ended June 30, 2025 and 2024, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
(5)Amounts primarily consist of amortization of acquired intangible assets purchased in connection with business acquisitions and capitalized software for internal use as well as depreciation and amortization of property, plant, and equipment, net.
(6)Long-lived assets consist of property, plant, and equipment, net and capitalized software.
Schedule of Long-lived Assets By Geographic Areas
Long-lived assets by geographic areas were as follows:
(In millions)June 30, 2025March 31, 2025
Long-lived assets
United States$2,952 $2,877 
Foreign330 306 
Total long-lived assets$3,282 $3,183